Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2009

View Archived Issues

Novel GABA(A) modulator shows antinociceptive activity in vivo

Biodel to submit NDA for VIAject to FDA for diabetes

Studies with SAR-150640 show potential importance of ADRB3 agonists in preventing preterm labor

Studies determine optimal doses of sublingual immunotherapy with rBet v 1

Combination of paclitaxel and cyclophosphamide is safe in patients with bladder cancer

DSMB recommends continuation of Anthera's phase II IMPACTS clinical trial of A-001

Teva to use Compugen biomarkers for detection of drug-induced kidney toxicity

AVEO and Biogen sign definitive agreement for ErbB3-targeted antibodies

Gilead initiates phase II cicletanine trial for pulmonary arterial hypertension

FDA approves new indication for Wyeth's Tygacil

Novel orally bioavailable alkyl amines display in vivo renin inhibitory activity

Fablyn approved in Europe for the treatment of osteoporosis

Clinical study shows potential of kisspeptin-54 as a treatment for infertility

CV Therapeutics develops candidate SCD inhibitor for obesity, metabolic syndrome and diabetes

Novel IGF-1R inhibitor BMS-754807 in phase I development

CFFT grants Alnara exclusive worldwide rights to PERT therapy liprotamase

Nerviano Medical Sciences claims substituted indazole derivatives as kinase inhibitors

Oncolytics completes patient enrollment in REO 009 clinical trial of Reolysin and Gemzar

Novel pyrazoloquinoline and pyrazolonaphthyridine derivatives claimed by Novartis

HGS and Morphotek sign collaboration agreement for therapeutic monoclonal antibodies

Novartis claims novel parathyroid calcium-sensing receptor antagonists

NovaBay and Galderma sign global agreement to develop and commercialize Aganocide

Abilify oral solution 0.1% to be launched in Japan in April

Novel alpha-alkyl substituted N-acyltryptophanols discovered by Bayer Schering Pharma

Additional indication for Actos approved in Japan

Eisai claims novel polycyclic compounds against beta-amyloid load

Vertex commences phase II development for VX-809 in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...